Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
| Autor: | Mehdi Khellaf, Anaïs Charles-Nelson, Olivier Fain, Louis Terriou, Jean-François Viallard, Stéphane Cheze, Julie Graveleau, Borhane Slama, Sylvain Audia, Mikael Ebbo, Guillaume Le Guenno, Manuel Cliquennois, Gilles Salles, Caroline Bonmati, France Teillet, Lionel Galicier, Arnaud Hot, Olivier Lambotte, François Lefrère, Salimatou Sacko, Dieudonné Kilendo Kengue, Philippe Bierling, Françoise Roudot-Thoraval, Marc Michel, Bertrand Godeau |
|---|---|
| Předmět: |
Adult
Male medicine.medical_specialty Immunology Biochemistry Disease-Free Survival Antibodies Monoclonal Murine-Derived Recurrence immune system diseases Cause of Death hemic and lymphatic diseases Internal medicine medicine Humans Prospective Studies Registries Prospective cohort study Aged Cause of death Purpura Thrombocytopenic Idiopathic business.industry Incidence (epidemiology) Cell Biology Hematology Middle Aged Clinical trial Regimen Treatment Outcome Relative risk Monoclonal Female Rituximab business medicine.drug |
| Zdroj: | Europe PubMed Central |
| Popis: | We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response. In total, 173 patients received 4 infusions of 375 mg/m(2) and 72 received 2 fixed 1-g infusions 2 weeks apart. The choice of the rituximab regimen was based on the physician's preference and not patient characteristics. Overall, 38 patients showed minor intolerance to rituximab infusions; infusions had to be stopped for only 3 patients. Seven showed infection (n = 11 cases), with an incidence of 2.3 infections/100 patient-years. Three patients died of infection 12 to 14 months after rituximab infusions, but the role of rituximab was questionable. In total, 152 patients (61%) showed an overall initial response (platelet count ≥30 × 10(9)/L and ≥2 baseline value). At a median follow-up of 24 months, 96 patients (39%) showed a lasting response. On multivariate analysis, the probability of sustained response at 1 year was significantly associated with ITP duration |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|